CN1613478A - Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof - Google Patents
Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof Download PDFInfo
- Publication number
- CN1613478A CN1613478A CN 200310108461 CN200310108461A CN1613478A CN 1613478 A CN1613478 A CN 1613478A CN 200310108461 CN200310108461 CN 200310108461 CN 200310108461 A CN200310108461 A CN 200310108461A CN 1613478 A CN1613478 A CN 1613478A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- medicine composition
- extract
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A Chinese medicine for removing excessive fat and losing weight by orally taking it is prepared from green tea, rhubarb, gingko leaf and milkvetch seed. Its advantage is high effect.
Description
Technical field:
The present invention relates to the Chinese medicine health care product field, be specifically related to a kind of Chinese medicine composition and preparation method with functions of lowering blood-fat and reducing weight.
Background technology:
In recent years, the sickness rate of affluence diseases such as China's hypertension, hyperlipemia, coronary heart disease, diabetes, obesity obviously rises, and has caused the concern of the whole society.This class disease is the first killer who threatens middle-aged and elderly people health, the very close diseases of dependency such as hyperlipemia, diabetes, obesity, and its addition total incidence is 10%, considers compound predisposing factor, remains serious problem.
Since lipid metabolism or running one or more lipids of blood plasma are higher than normally be called hyperlipemia (hyperlipemia, hp).Lipid is insoluble or be slightly soluble in water and must exist with the lipoprotein form with protein bound, and therefore, hyperlipemia often is a hyperlipoproteinemia (hyperlipoproteinemia).Hyperlipoproteinemia refers to serum lipoprotein concentration and raises.
Difference according to lipoprotein component content is classified, as high vldl C-VLDL mass formed by blood stasis, high ldl cholesterol and high hdl hypercholesterolemia.Generally acknowledged hyperlipemia at present, comprise that hypercholesterolemia (hypercholesterolemia), hypertriglyceridemia (hypertriglyceridemia) and plyability hyperlipemia are one of main hazard factors that promotes atherosclerosis and the coronary atherosclerotic heart disease (chd) that jeopardizes human health, and blood fat reducing can reduce the incidence rate of coronary atherosclerotic heart disease.Data shows according to statistics, and every hypercholesterolemia reducing level is equal 1%, can reduce the incidence rate of 2% myocardial infarction.In addition, the reduction of blood fat has been proved the progress of established atherosclerotic plaque that can slow down, even it is disappeared, and might lower the case fatality rate of coronary atherosclerotic heart disease.Therefore, over nearly 20 years, whole world medical circle is very paid attention to the research of hyperlipemia.
Treatment is to change unusual blood fat situation and reduce the risk that coronary heart disease takes place with the significance of control hyperlipemia, and Therapeutic Method generally is divided into Drug therapy and non-drug therapy two aspects.The control of hyperlipemia generally needs to carry out for a long time even throughout one's life, required appropriate litigation fees costliness, and all fat-reducing medicaments all have certain toxic and side effects at present, and part Study data result shows that pharmaceutical intervention (being non-that spit of fland class lipid lowerers especially) can not make crowd's general mortality rate reduce.Therefore, must emphasize non-drug therapy, the especially health care and the necessity of dietetic therapy, this is first-selection and basic measures that hyperlipemia is treated.
Summary of the invention:
Technical problem to be solved by this invention is according to Chinese medical theory, and a kind of safe in utilization, significant Chinese medicine health care product compositions of functions of lowering blood-fat and reducing weight is provided.
Chinese medicine composition with functions of lowering blood-fat and reducing weight disclosed by the invention is to mince and/or extract is the various oral formulations of active ingredient with medical material green tea, Radix Et Rhizoma Rhei, Folium Ginkgo and Semen Astragali Complanati coarse powder.
The weight percent of described each medical material of active ingredient consists of green tea 30-72%, Radix Et Rhizoma Rhei 10-30%, Folium Ginkgo 10-25%, Semen Astragali Complanati 8-15%.
Described various oral formulations comprises teabag, granule, capsule, tablet, oral liquid etc.
When active ingredient minces for each medicinal material coarse powder and/or during extract, can be made into teabag; The addition of extract is 0.2-1 a times that medicinal material coarse powder minces; When active ingredient is each medicinal substances extract, can make various other oral formulations with pharmaceutic adjuvant, as granule, capsule, tablet, oral liquid etc., the percentage by weight that this moment, extract and pharmaceutic adjuvant respectively accounted for is 20～80% and 80～20%.
Another technical problem to be solved by this invention is to disclose above-mentioned Chinese medicine health care product preparation of compositions method.
The present invention has the Chinese medicine composition of functions of lowering blood-fat and reducing weight, makes by following technical proposals:
1, oral formulations preparation
(1) extract preparation
Take by weighing 30-72% green tea, 10-30% Radix Et Rhizoma Rhei, 10-25% Folium Ginkgo, 8-15% Semen Astragali Complanati, carry 2 times with 8 times of water gagings, extraction time was respectively 1.5 hours, 1 hour, the ultracentrifugation solid-liquid separation, merge extractive liquid, is evaporated to medicinal liquid proportion 1.06-1.15, spray drying, promptly;
(2) formulation preparation
Get the said extracted thing, press recipe quantity, adopt the conventional formulation method to make tablet, granule, capsule or oral liquid; The pharmaceutic adjuvant that uses in the preparation is the pharmaceutical adjunct of routine.
2, the preparation of teabag
Take by weighing 30-72% green tea, 10-30% Radix Et Rhizoma Rhei, 10-25% Folium Ginkgo, 8-15% Semen Astragali Complanati, 60 ℃ of dryings, water content 3-10% is crushed to the 10-40 order, and packing is promptly;
Or add the extract that makes in the 0.2-1 above-mentioned oral formulations doubly in the medicinal material coarse powder after pulverizing, and to granulate, packing is promptly.
Technical problem to be solved by this invention is to disclose the application of above-mentioned Chinese medicine composition in preparation lowering blood-fat and reducing weight health product.
Prescription of the present invention is to be guideline with the Chinese medical theory, meets Chinese medicine health care theory: hyperlipidemia system is by growing the food delicious food, hypokinesia, and absorption increases, consumption reduces and causes essence from turbidization, condenses to be expectorant, and it is turbid to turn to fat, the stasis of blood is in venation, and the stasis of blood is then heat-transformation for a long time, and heat is burnt, and blood is sticking to form.Control suitable blood fat reducing, clearing away heat from blood, blood stasis dispelling is turbid, the network of promoting blood circulation.Green tea refresh oneself in the side, reduce phlegm turbid, diuresis and blood fat reducing, Radix Et Rhizoma Rhei clearing away heat-fire, blood circulation promoting and blood stasis dispelling, and clearing away heat from blood, blood stasis dispelling, the network of promoting blood circulation, turbid, the network of promoting blood circulation of Folium Ginkgo blood stasis dispelling, Semen Astragali Complanati the kidney invigorating nourishing the liver consolidates.Weization are turbid, promote blood circulation, heat clearing away, and double consolidating, and have reached to attack and not high, mend and oiliness effect.
Prove according to the modern pharmacology drug effect simultaneously: bioactive substances such as the tea polyphenols that contains in the green tea, tea pigment.Can obviously increase and reduce serum cholesterol and low-density lipoprotein cholesterol, green tea has good hypolipemic function; The main chemical compositions of Radix Et Rhizoma Rhei has anthraquinone derivative and tannin isoreactivity material, studies show that, influences digestion and metabolism performance weight losing function thereby Radix Et Rhizoma Rhei increases the bile amount by the pancreatin secretion, and Radix Et Rhizoma Rhei has the blood lipid regulation function simultaneously; Flavone in the Folium Ginkgo has the level of T-CHOL and triglyceride in the obvious reduction serum, thereby reaches the function of blood lipid regulation; Semen Astragali Complanati contains materials such as aminoacid, polypeptide, protein, flavone, and wherein semen astragali complanati general flavone has tangible effect for reducing blood fat.
Chinese medicine composition of the present invention is carried out the pharmacology and the toxicity test of relevant blood activating and fat reducing health care.
1, blood fat reducing pharmacological testing
(1) experiment material
The I animal: the SD rat, male, provide the quality certification number by the laboratory animal department of the Chinese Academy of Sciences of Central South University: No. 152, the moving word in Hunan Province.Body weight 180-220g, raising condition: raise by the inbred animal requirement.
II instrument and reagent: Kang Ren 560 automatic clinical chemistry analyzers.
Testing cassete TC, the biological company limited of east, TG Wenzhou bowl
Testing cassete HDL-C Yi Likang Bioisystech Co., Ltd
The III medicine
(I) blood activating and fat reducing teabag (self-control) is a chocolate brown powder shape granule, teabag, and lot number: 20030108, get 670 gram samples, soak 3-5min with boiling water during use, repeat to soak 2 times, merge 2 times soak, be concentrated into 1000ml, standby.
IV high lipid food: normal feedstuff 79%, cholesterol 1%, yolk powder 10%, Adeps Sus domestica 10%
(2) experimental technique and result
I, with after one week of normal feedstuff feed rat, fasting 14 hours, get tail blood and measure serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C) with Kang Ren 560 automatic clinical chemistry analyzers, according to the TC level animal is divided into 4 groups at random: high fat matched group and three are organized by examination.From on-test just, each treated animal is used high lipid food instead, is tried the thing group and irritates stomach by above-mentioned dosage design and give different volumes blood activating and fat reducing soak, high fat matched group gives the distilled water with volume, continuous 30 days, fasting 14 hours was pulled out the eyeball blood sampling and is measured every blood lipids index.
II, assay:
With 0.335,0.670, the self-control blood activating and fat reducing product of 2.010g/kg.bw dosage is given and rat oral gavage 30 days, compare with high fat matched group, 2.010g/kg.bw the dosage group can obviously reduce high lipid food Serum TC, TG level, (P＜0.05), rat blood serum HDL-C level is not had obvious influence (P＞0.05), and prompting blood activating and fat reducing product has the auxiliary antilipemic effect.
2, fat-reducing pharmacological testing
With 0.335,0.670,2.010g/kg.bw the self-control blood activating and fat reducing product of dosage is given and rat oral gavage 30 days, the body weight of each dosage group, weight gain, body fat weight in wet base, body fat/weight ratio and matched group more all have decline, 2.010g/kg.bw dosage group body weight, weight gain and matched group are relatively, difference has significance (P＜0.01), 0.670,2.010g/kg.bw dosage group body fat weight in wet base, 2.010g/kg.bw dosage group body fat/weight ratio and matched group are relatively, difference has significance (P＜0.01,0.05), prompting blood activating and fat reducing health promoting product has auxiliary antiobesity action.
3, fat-reducing clinical trial
The experimenter used the blood activating and fat reducing health promoting product 30 days continuously, and body weight, body fat total amount, body fat percentage all descend, weight average decline 2.7kg, the average 2.4kg of body fat gross weight, body fat percentage rate on average descends 2.0%, and subcutaneous fat thickness all descends, wherein, the triangular muscle place reduces 5.3mm, and omoplate reduces 4.5mm in the place down, the other place of umbilicus reduces 7.0mm, the 4.6mm of condyle sour jujube place, waistline 5.6mm, hip circumference reduces 3.1mm, with comparing difference before the test significance (P＜0.05,0.01 or P＜0.001) is arranged all.All in range of normal value, exercise tolerance does not fall the every clinical indices of experimenter as follows, this shows that the blood activating and fat reducing health promoting product has antiobesity action to human body, and body health is not had obvious damage before and after the test.
4, toxicity and safety
(1), female, male chmice acute per os LD50 is greater than 21500mg/kg.bw, belongs to non-poisonous material
(2), three genetoxic experiments (Salmonella reversion test, mouse bone marrow cells are had a liking for many property and incarnadined cell micronucleus test, mouse sperm deformity experiment) result is all negative.
(3), fed the result in 30 days: with 6.70,3.35,1.68g/kg.bw the blood activating and fat reducing health promoting product gave rat oral gavage 30 days, duration of test, each treated animal growth promoter is good, each dosage group weight gain, food utilization, routine blood test index (hemoglobin, the erythrocyte sum, packed cell volume, total number of blood platelet, total white blood cells and classification), blood biochemistry index (serum glutamic pyruvic transminase, the third careless ammonia enzyme, total protein, albumin, cholesterol, triglyceride, blood urea nitrogen, creatinine, blood glucose), organ coefficient (liver/body, spleen/body, the testis of kidney/body ratio and male Mus/body weight ratio) compares there was no significant difference (P＞0.05) with matched group.Gross anatomy is not seen relevant abnormal change with sample with tissue pathology checking, illustrates that the blood activating and fat reducing health promoting product does not produce obvious toxic-side effects through nursing in 30 days to the every observation index of rat.
Above-mentioned test shows that Chinese medicine composition safety non-toxic of the present invention has auxiliary antilipemic effect and antiobesity action, is a kind of lowering blood-fat and reducing weight health product of exact efficacy.
The specific embodiment:
The preparation of embodiment 1, teabag
Prescription: green tea (5500 gram), Radix Et Rhizoma Rhei (1500 gram), Folium Ginkgo (1500 gram), Semen Astragali Complanati (1500 gram)
The coarse powder of getting this prescription 1000 grams that mince divide to be filled in the teabag inner packing Cotton Gossypii paper bag, outer package paper bag again, and loading amount 2 grams promptly get the blood activating and fat reducing teabag.
The preparation of embodiment 2 extracts
Green tea (4800 gram), Radix Et Rhizoma Rhei (1700 gram), Folium Ginkgo (2200 gram), Semen Astragali Complanati (1300 gram), take by weighing green tea, Radix Et Rhizoma Rhei, Folium Ginkgo, Semen Astragali Complanati in proportion, carry 2 times with 8 times of water gagings, extraction time was respectively 1.5 hours, 1 hour, the ultracentrifugation solid-liquid separation, merge extractive liquid, is evaporated to medicinal liquid proportion 1.06-1.15, spray drying promptly gets extract.
Embodiment 3, teabag preparation
Green tea (5200 gram), Radix Et Rhizoma Rhei (2200 gram), Folium Ginkgo (1450 gram), Semen Astragali Complanati (1150 gram); the coarse powder of getting this prescription 2500 grams that mince; extract 500 grams that embodiment 2 makes; mix homogeneously; make 12-40 order granule; divide to be filled in the teabag inner packing Cotton Gossypii paper bag, place the outer package paper bag again, loading amount 2 grams promptly get the blood activating and fat reducing teabag.
Embodiment 4, preparation tablets
Green tea (5700 restrain), Radix Et Rhizoma Rhei (1600 gram), Folium Ginkgo (1450 gram), Semen Astragali Complanati (1250 gram) are got extract 500 grams that make by embodiment 2 methods with above-mentioned prescription, pulverizing, cross 80 mesh sieves, add appropriate amount of auxiliary materials, dextrin 100 grams, low-substituted hydroxypropyl cellulose 100 grams 75% ethanol are granulated, cross 14 mesh sieves, 60 ℃ of dryings are crossed 18 mesh sieve granulate and are made, and add magnesium stearate 6 grams, mix homogeneously, tabletting, sheet weigh 0.5 gram, promptly get the blood activating and fat reducing sheet.
Embodiment 5, granule preparation
Green tea (4600 restrain), Radix Et Rhizoma Rhei (1500 gram), Folium Ginkgo (2450 gram), Semen Astragali Complanati (1450 gram) are got extract 500 grams that make by embodiment 2 methods with above-mentioned prescription, pulverizing, cross 80 mesh sieves, add appropriate amount of auxiliary materials, dextrin 200 grams, aspartame 10 grams, 50% ethanol is granulated, and crosses 14 mesh sieves, 60 ℃ of dryings, crossing 18 mesh sieve granulate makes, divide to be filled in the thin aluminum bag, loading amount is 2 grams, promptly gets the blood activating and fat reducing granule.
Embodiment 6, capsule preparation
Green tea (5300 gram), Radix Et Rhizoma Rhei (2500 gram), Folium Ginkgo (1100 gram), Semen Astragali Complanati (1100 gram) are got extract 500 grams that make by embodiment 2 methods with above-mentioned prescription, pulverize, cross 80 mesh sieves, add appropriate amount of auxiliary materials, dextrin 200 grams, 75% ethanol is granulated, and crosses 14 mesh sieves, 60 ℃ of dryings, crossing 18 mesh sieve granulate makes, divide to be filled in the capsule, loading amount is 0.35 gram, promptly gets the blood activating and fat reducing capsule.
Embodiment 7, oral liquid preparation
Green tea (4900 gram), Radix Et Rhizoma Rhei (2300 gram), Folium Ginkgo (1700 gram), Semen Astragali Complanati (1100 gram), get extract 500 grams that make by embodiment 2 methods with above-mentioned prescription, be dissolved in 1500 ml waters, add 1500 milliliters of 95% ethanol, 4 ℃ of following sedimentations 12 hours, centrifugal filtration, ethanol is flung in decompression, adds aspartame 4 grams, adding distil water is settled to 10000, in fill to 100 ml container, sterilization promptly gets the blood activating and fat reducing oral liquid.
Claims (10)
1, a kind of Chinese medicine composition with functions of lowering blood-fat and reducing weight is characterized in that said composition is to mince and/or extract is the various oral formulations of active ingredient with medical material green tea, Radix Et Rhizoma Rhei, Folium Ginkgo and Semen Astragali Complanati coarse powder.
2, Chinese medicine composition according to claim 1 is characterized in that the weight percent of wherein said each medical material of active ingredient consists of green tea 30-72%, Radix Et Rhizoma Rhei 10-30%, Folium Ginkgo 10-25%, Semen Astragali Complanati 8-15%.
3, Chinese medicine composition according to claim 1 is characterized in that wherein said oral formulations is teabag, granule, capsule, tablet or oral liquid.
4, according to claim 1 or 3 described Chinese medicine compositions, it is characterized in that when active ingredient be medical material green tea, Radix Et Rhizoma Rhei, Folium Ginkgo and Semen Astragali Complanati coarse powder mince and/or during extract the dosage form of its oral formulations be teabag.
According to claim 1 or 3 described Chinese medicine compositions, it is characterized in that when active ingredient is the extract of medical material green tea, Radix Et Rhizoma Rhei, Folium Ginkgo and Semen Astragali Complanati that 5, the oral formulations dosage form made from pharmaceutic adjuvant is granule, capsule, tablet or oral liquid.
6, Chinese medicine composition according to claim 4 is characterized in that being minced by medical material green tea, Radix Et Rhizoma Rhei, Folium Ginkgo and Semen Astragali Complanati coarse powder and extract when forming when wherein said teabag, the addition of extract be the 0.2-1 that minces of medicinal material coarse powder doubly.
7, Chinese medicine composition according to claim 5 is characterized in that the weight percent of extract and pharmaceutic adjuvant consists of 20～80% and 80～20% in the wherein said oral formulations.
8, the preparation method of Chinese medicine composition according to claim 1 is characterized in that the preparation of wherein said oral formulations comprises the following steps:
(1) extract preparation
Take by weighing 30-72% green tea, 10-30% Radix Et Rhizoma Rhei, 10-25% Folium Ginkgo, 8-15% Semen Astragali Complanati, carry 2 times with 8 times of water gagings, extraction time was respectively 1.5 hours, 1 hour, the ultracentrifugation solid-liquid separation, merge extractive liquid, is evaporated to medicinal liquid proportion 1.06-1.15, spray drying, promptly;
(2) formulation preparation
Get the said extracted thing, press recipe quantity, adopt the conventional formulation method to make tablet, granule, capsule or oral liquid; The pharmaceutic adjuvant that uses in the preparation is the pharmaceutical adjunct of routine.
9, the preparation method of Chinese medicine composition according to claim 1 is characterized in that the preparation of wherein said teabag comprises the following steps:
Take by weighing 30-72% green tea, 10-30% Radix Et Rhizoma Rhei, 10-25% Folium Ginkgo, 8-15% Semen Astragali Complanati, 60 ℃ of dryings, water content 3-10% is crushed to the 10-40 order, and packing is promptly;
Or add the 0.2-1 extract that makes by claim 8 method doubly in the medicinal material coarse powder after pulverizing, and to granulate, packing is promptly.
10, the application of Chinese medicine composition according to claim 1 in preparation lowering blood-fat and reducing weight health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101084612A CN100358553C (en) | 2003-11-06 | 2003-11-06 | Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101084612A CN100358553C (en) | 2003-11-06 | 2003-11-06 | Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1613478A true CN1613478A (en) | 2005-05-11 |
| CN100358553C CN100358553C (en) | 2008-01-02 |
Family
ID=34758599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101084612A Expired - Fee Related CN100358553C (en) | 2003-11-06 | 2003-11-06 | Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100358553C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697962A (en) * | 2012-06-12 | 2012-10-03 | 白华 | Lymph static defatting weight-losing paste |
| CN106689568A (en) * | 2015-11-14 | 2017-05-24 | 陈国志 | Dendrobenthamia japonica parasite weight reducing tea |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100365110C (en) * | 2002-04-17 | 2008-01-30 | 范凯 | Sedative kidney-reinforcing medicinal liquor |
-
2003
- 2003-11-06 CN CNB2003101084612A patent/CN100358553C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697962A (en) * | 2012-06-12 | 2012-10-03 | 白华 | Lymph static defatting weight-losing paste |
| CN102697962B (en) * | 2012-06-12 | 2013-12-25 | 白华 | Lymph static defatting weight-losing paste |
| CN106689568A (en) * | 2015-11-14 | 2017-05-24 | 陈国志 | Dendrobenthamia japonica parasite weight reducing tea |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100358553C (en) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885304A (en) | BMD (bone mineral density)-increased health food composite and preparation method thereof | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN1058614C (en) | Galenic composition | |
| CN111228238B (en) | Pharmaceutical composition containing orlistat and oligosaccharide | |
| CN1528429A (en) | Chinese medicine preparation with accessory protection action to alcoholic liver injury and preparing method thereof | |
| CN1709454A (en) | Chinese medicine formulation for treating arthrolithiasis, and its preparing method | |
| CN1709451A (en) | Underleaf pearl formulation for treatig liver-gallbladder diseases and its preparing method | |
| CN101020016B (en) | Medicine for treating fracture and injured tendon and its preparation | |
| CN100358553C (en) | Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN1907432A (en) | Application of polysaccharide from the Gastrodia elata Blume in health caring stuff and medicine | |
| CN104740088A (en) | Weight reduction compound composition and preparation method thereof | |
| CN1159029C (en) | Blood lipoid regulating medicine and its prepn | |
| CN1706453A (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN1309367C (en) | Preparation of Chinese traditional medicine for curing gallstone and preparation method | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN1199683C (en) | Medicine combination for reducing blood fat and preventing senescence and its medicines | |
| CN110664903A (en) | Composition with blood fat reducing function and preparation method and application thereof | |
| CN101066425A (en) | Chinese medicine prepn for treating ungual mycosis | |
| CN1209115C (en) | Active extracted composition of teasel root and notoginseng and use in medicine | |
| CN1456309A (en) | Antilipemic antiatherosclerosis medicine composition and preparing method, application thereof | |
| CN1562177A (en) | Chinese materia medica preparation for treating hysteromyoma and preparation method | |
| JP2004238349A (en) | Antiobestic agent or/and prophylactic agent for arteriosclerosis containing terminalia catappa as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| DD01 | Delivery of document by public notice |
Addressee: Shanghai Institute of traditional Chinese medicine Finance Document name: Notification of Approving Refund |